香砂六君子汤联合XELOX化疗及贝伐珠单抗靶向治疗对晚期结肠癌患者近期疗效及肿瘤标志物的影响

Effect of Xiangsha Liujunzi Decoction Combined with XELOX Chemotherapy and Bevacizumab Targeting Therapy on Short-term Efficacy and Tumor Markers in Patients with Advanced Colon Cancer

目的:探讨香砂六君子汤联合XELOX化疗及贝伐珠单抗靶向治疗对晚期结肠癌患者近期疗效及肿瘤标志物的影响。方法:选取2020年1月—2023年10月南平市人民医院收治的105例晚期结肠癌患者作为研究对象,随机分为观察组(n=54)和对照组(n=51)。对照组采用XELOX化疗及贝伐珠单抗靶向治疗,观察组在对照组基础上联合香砂六君子汤治疗。比较两组近期疗效、免疫功能、肿瘤标志物[糖类抗原242(CA242)、糖类抗原199(CA199)、癌胚抗原(CEA)]水平及不良反应发生情况。结果:观察组客观缓解率(ORR)、疾病控制率(DCR)分别为51.85%、68.52%,均高于对照组的31.37%、49.02%,差异有统计学意义(P<0.05)。治疗后,两组CD3^(+)、CD4^(+)水平低于治疗前,CD8^(+)水平高于治疗前,但观察组CD3^(+)、CD4^(+)水平高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。治疗后,两组CA242、CA199、CEA水平均低于治疗前,且观察组CA242、CA199、CEA水平均低于对照组,差异有统计学意义(P<0.05)。观察组胃肠道反应发生率为37.04%,低于对照组的56.86%,差异有统计学意义(P<0.05);两组脱发、贫血、周围神经毒性及肝肾功能损伤发生率比较,差异无统计学意义(P>0.05)。结论:香砂六君子汤联合XELOX化疗及贝伐珠单抗靶向治疗可提高晚期结肠癌近期效果,减轻机体免疫功能损伤,降低肿瘤标志物表达水平,且安全性良好。

Objective:To investigate the effect of Xiangsha Liujunzi Decoction combined with XELOX chemotherapy and Bevacizumab targeting therapy on the short-term efficacy and tumor markers in patients with advanced colon cancer.Method:A total of 105 patients with advanced colon cancer admitted to Nanping People's Hospital from January 2020 to October 2023 were selected as the study objects and randomly divided into observation group(n=54)and control group(n=51).The control group was treated with XELOX chemotherapy and Bevacizumab targeting therapy,and the observation group was treated with Xiangsha Liujunzi Decoction on the basis of the control group.The short-term efficacy,immune function,tumor markers[carbohydrate antigen 242(CA242),carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA)]levels and the occurrence of adverse reactions between the two groups were compared.Result:The objective response rate(ORR)and disease control rate(DCR)in the observation group were 51.85% and 68.52%,respectively,which were higher than 31.37% and 49.02% in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in two groups were lower than those before treatment,and the level of CD8^(+)were higher than those before treatment,but the levels of CD3^(+)and CD4^(+)in the observation group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the CA242,CA199 and CEA levels in two groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of gastrointestinal reaction in the observation group was 37.04%,which was lower than 56.86% in the control group,the difference was statistically significant(P<0.05).There were no significant differences in the incidence of alopecia,anemia,peripheral nerve toxicity and liver and kidney function injury between two groups(P>0.05).Conclusion:Xiangsha Liujunzi Decoction combined with XELOX chemotherapy and Bevacizumab targeted therapy can improve the short-term efficacy of advanced colon cancer,effectively improve the immune function of body,reduce the expression level of tumor markers,and have good safety.